Is Novo Nordisk Stock a Bargain Right Now?

Novo Nordisk has been displaced by Eli Lilly in the GLP-1 weight‑loss market, sending NVO shares down more than 50% since mid‑2024, but its valuation now looks inexpensive (P/E ~18 vs Lilly ~50; five‑year P/E averages: NVO 30, LLY 55). Novo yields ~2.8% with a dividend payout ratio near 40%, underpinned by its recurring insulin business and recent GLP‑1 pill launch that could help recapture share; competitors including Lilly and Pfizer are also advancing GLP‑1 portfolios. For value- and dividend-focused investors, the article frames Novo as a potential bargain despite competitive headwinds.

Analysis

Market structure: The immediate winners are momentum buyers and Eli Lilly (LLY) capturing GLP‑1 market share; losers include previously premium‑priced Novo Nordisk (NVO) equity which has seen >50% drawdown since mid‑2024 and short‑term sentiment. NVO still controls annuity insulin cash flows and a 2.8% yield versus LLY’s 0.6%, implying different investor cohorts (value/dividend vs. growth/momentum). The current P/E spread (~18 NVO vs ~50 LLY; NVO 5‑yr avg 30) signals a valuation swing rather than fundamental annihilation.

Risk assessment: Tail risks include payer formulary contraction or reimbursement cuts (US Medicare/Medicaid), an adverse safety/regulatory finding across the GLP‑1 class, or manufacturing shortfalls — any could remove upside or catalyze further multiple compression. Time buckets: days (volatility spikes around sales/earnings), weeks–months (script trends, payer decisions, GLP‑1 pill launches), quarters–years (market share and margin reversion). Hidden deps: market share hinges on pricing, pill vs injection preference, and production capacity; FX exposure (DKK/USD) can amplify reported results.

Trade implications: Direct play is value‑oriented long NVO sized as a 2–3% position accumulated in tranches (50% now, 50% on −10–15%); pair trade (long NVO / short LLY dollar‑neutral, 1–2% net) targets P/E convergence over 6–12 months. Options: buy 9–18 month NVO call spreads or LEAPS for asymmetric upside, or sell covered calls to harvest the 2.8% yield plus premium. Rotate 1–3% from high‑valuation pharma growth into dividend/value healthcare and increase cash for event risk around next two earnings cycles.

Contrarian angle: Consensus underweights NVO’s insulin annuity and overweights a permanent GLP‑1 franchise loss — the valuation implies >40% multiple overcorrection versus its history. Historical parallels (momentum leaders losing premium then re‑rating) suggest a 12–24 month mean reversion is plausible if NVO stabilizes script trends or proves pill advantage. Unintended consequences: aggressive LLY outperformance risks regulatory scrutiny and payer pushback, which would flip flows quickly; that makes a time‑limited, size‑controlled contrarian position attractive.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in NVO (buy in two tranches: 50% immediately, 50% on an additional 10–15% share price decline). Target a 30–40% upside over 12–24 months if P/E reverts toward 25–30; set a hard stop‑loss at −25% from cost or convert to covered calls if down 15%.
• Implement a dollar‑neutral pair trade: long NVO / short LLY sized 1–2% of portfolio exposure (equal dollar notional). Horizon 6–12 months; close on P/E convergence (~half the current spread) or if LLY P/E drops below 40 or NVO P/E rises above 25.
• Use options for asymmetric payoff: buy 9–18 month NVO call spreads (buy ATM, sell 1.2x strike) to limit premium outlay; alternatively sell 3–6 month covered calls on existing NVO holdings to capture ~3–5% annualized extra yield. Reassess after next two earnings releases.
• Trim 20–40% of recent LLY gains (take profits) and redeploy proceeds to NVO or cash to reduce momentum concentration risk. Monitor weekly US GLP‑1 TRx trends, monthly script market‑share reports, and any payer/formulary announcements over the next 60–90 days as explicit catalysts to add/trim positions.